Home
/
CORCEPT THERAPEUTICS INC
/
Financials
/
Quarterly
CORCEPT THERAPEUTICS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that CORCEPT THERAPEUTICS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$207.64M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$194.43M
Jul 31, 2025
Q1
2025
Mar 31, 2025
$157.21M
May 5, 2025
Q3
2025
Sep 30, 2024
$182.55M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$163.80M
Jul 31, 2025
Q1
2025
Mar 31, 2024
$146.81M
May 5, 2025
Q3
2024
Sep 30, 2023
$123.60M
Oct 30, 2024
Q2
2024
Jun 30, 2023
$117.72M
Jul 29, 2024
Q1
2024
Mar 31, 2023
$105.65M
May 1, 2024
Q3
2023
Sep 30, 2022
$101.73M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$103.39M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$93.69M
May 3, 2023
Q3
2022
Sep 30, 2021
$96.13M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$91.59M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$79.44M
May 5, 2022
Q3
2021
Sep 30, 2020
$86.33M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$88.57M
Jul 29, 2021
Q1
2021
Mar 31, 2020
$93.25M
May 6, 2021
Q3
2020
Sep 30, 2019
$81.51M
Nov 3, 2020
Q2
2020
Jun 30, 2019
$72.26M
Aug 4, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2012
Mar 31, 2012
$1.01M
May 10, 2012
Q3
2011
Sep 30, 2011
$1.01M
Nov 8, 2011
Q2
2011
Jun 30, 2011
$1.01M
Aug 9, 2011
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$19.67M
Nov 4, 2025
Q3
2025
Jun 30, 2025
$35.15M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$35.15M
Jul 31, 2025
Q2
2025
Mar 31, 2025
$20.55M
Jul 31, 2025
Q3
2025
Mar 31, 2025
$20.55M
Nov 4, 2025
Q1
2025
Mar 31, 2025
$20.55M
May 5, 2025
Q3
2025
Sep 30, 2024
$47.21M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$35.49M
Jul 31, 2025
Q3
2025
Jun 30, 2024
$35.49M
Nov 4, 2025
Q2
2025
Mar 31, 2024
$27.76M
Jul 31, 2025
Q1
2025
Mar 31, 2024
$27.76M
May 5, 2025
Q3
2025
Mar 31, 2024
$27.76M
Nov 4, 2025
Q3
2024
Sep 30, 2023
$31.38M
Oct 30, 2024
Q3
2024
Jun 30, 2023
$27.53M
Oct 30, 2024
Q2
2024
Jun 30, 2023
$27.53M
Jul 29, 2024
Q1
2024
Mar 31, 2023
$15.88M
May 1, 2024
Q2
2024
Mar 31, 2023
$15.88M
Jul 29, 2024
Q3
2024
Mar 31, 2023
$15.88M
Oct 30, 2024
Q3
2023
Sep 30, 2022
$34.61M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$27.41M
Aug 2, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$10.22M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$26.68M
Jul 31, 2025
Q1
2025
Mar 31, 2025
$3.42M
May 5, 2025
Q3
2025
Sep 30, 2024
$46.60M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$35.59M
Jul 31, 2025
Q1
2025
Mar 31, 2024
$29.50M
May 5, 2025
Q3
2024
Sep 30, 2023
$31.18M
Oct 30, 2024
Q2
2024
Jun 30, 2023
$29.58M
Jul 29, 2024
Q1
2024
Mar 31, 2023
$14.85M
May 1, 2024
Q3
2023
Sep 30, 2022
$31.93M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$31.43M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$26.77M
May 3, 2023
Q3
2022
Sep 30, 2021
$36.23M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$31.94M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$19.64M
May 5, 2022
Q3
2021
Sep 30, 2020
$24.72M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$35.26M
Jul 29, 2021
Q1
2021
Mar 31, 2020
$37.71M
May 6, 2021
Q3
2020
Sep 30, 2019
$33.00M
Nov 3, 2020
Q2
2020
Jun 30, 2019
$24.63M
Aug 4, 2020